Condition: Non-small Cell Lung Cancer · Sponsor: Teligene US
The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).
This description comes directly from the study's public registry record.
Xiaoyang Xia · 805-300-9373 · Xiaoyang.xia@teligene.com
Dawei Zhang · 805-300-1019 · david.zhang@teligene.com
Always discuss trial participation with your own doctor first.
| Oncology Physicians Network Healthcare | Glendale, California, United States | Withdrawn |
| University of California San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| University Cancer & Blood Center (UCBC) - Athens | Athens, Georgia, United States | Recruiting |
| Mission Cancer + Blood - Mission Cancer Foundation | Des Moines, Iowa, United States | Recruiting |
| Norton Cancer Institute - Downtown | Louisville, Kentucky, United States | Withdrawn |
| Northwell Health | New Hyde Park, New York, United States | Active Not Recruiting |
| Perlmutter Cancer Center - 34th Street | New York, New York, United States | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06010329